Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Volasertib |
Synonyms | |
Therapy Description |
Volasertib (BI 6727) inhibits polo-like kinase I (PLK1), resulting in cell cycle arrest and apoptosis in tumor cells (PMID: 27330107, PMID: 30782614, PMID: 32728610). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Volasertib | BI 6727|BI6727|BI-6727 | PLK1 Inhibitor 18 | Volasertib (BI 6727) inhibits polo-like kinase I (PLK1), resulting in cell cycle arrest and apoptosis in tumor cells (PMID: 27330107, PMID: 30782614, PMID: 32728610). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - RET | lung adenocarcinoma | predicted - sensitive | Volasertib | Preclinical - Patient cell culture | Actionable | In a preclinical study, a patient-derived lung adenocarcinoma cell line harboring EML4-RET was moderately sensitive to treatment with Volasertib (BI 6727) in culture (PMID: 33795352). | 33795352 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02721875 | Phase I | Azacitidine Volasertib | Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | Terminated | 1 |